Roivant Sciences Ltd (ROIV)

Jan 13, 2025, 9:00 AM EST - 4 days ago

Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development

Dec 4, 2024, 8:30 AM EST - 6 weeks ago

Roivant Sciences: A Biotech Growth Play With Major Ambitions

Dec 3, 2024, 7:19 AM EST - 6 weeks ago

Roivant's lung disease drug fails mid-stage trial

Nov 12, 2024, 2:41 PM EST - 2 months ago

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

Oct 29, 2024, 4:35 PM EDT - 2 months ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Oct 22, 2024, 12:31 PM EDT - 3 months ago

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Sep 18, 2024, 3:20 PM EDT - 4 months ago

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

OGN

Sep 18, 2024, 10:59 AM EDT - 4 months ago

Roivant Flips a Skin Drug to Organon

OGN

Sep 18, 2024, 7:30 AM EDT - 4 months ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

OGN

Sep 10, 2024, 6:30 AM EDT - 4 months ago

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

Sep 10, 2024, 6:30 AM EDT - 4 months ago

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

Sep 9, 2024, 12:54 PM EDT - 4 months ago

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Sep 9, 2024, 7:00 AM EDT - 4 months ago

Roivant Provides Update on Graves' Disease Development Program

Aug 30, 2024, 8:00 AM EDT - 5 months ago

Top Stocks Near Their 200-Day SMA

CCL CUK SM

Aug 22, 2024, 1:00 AM EDT - 5 months ago

Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses

Aug 9, 2024, 12:03 PM EDT - 5 months ago

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

Jun 7, 2024, 6:26 PM EDT - 8 months ago

The 'Undercovered' Dozen From June 1-6

ALNY CLOV CRSP ENVX GAM HAL LPA

Jun 2, 2024, 7:27 AM EDT - 8 months ago

Roivant Sciences: Executing On Huge Buyback Program With More To Come

May 30, 2024, 12:23 PM EDT - 8 months ago

Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript

May 30, 2024, 7:00 AM EDT - 8 months ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

May 16, 2024, 4:05 PM EDT - 8 months ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

Apr 25, 2024, 8:00 AM EDT - 9 months ago

Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis

Apr 2, 2024, 7:28 AM EDT - 10 months ago

Roivant's anti-inflammatory drug succeeds in mid-stage study

Apr 2, 2024, 7:00 AM EDT - 10 months ago

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Mar 18, 2024, 3:52 PM EDT - 10 months ago

Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success

Feb 13, 2024, 12:02 PM EST - 1 year ago

Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript

Feb 13, 2024, 7:00 AM EST - 1 year ago

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

Jan 7, 2024, 1:15 PM EST - 1 year ago

Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy

Dec 20, 2023, 4:30 PM EST - 1 year ago

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

Dec 14, 2023, 9:00 AM EST - 1 year ago

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

Nov 27, 2023, 8:52 AM EST - 1 year ago

Roivant Sciences shares drop as lupus treatment misses trial goal

Nov 27, 2023, 8:49 AM EST - 1 year ago

Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study

Nov 13, 2023, 7:19 PM EST - 1 year ago

Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript

Nov 13, 2023, 7:00 AM EST - 1 year ago

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

Oct 30, 2023, 5:30 PM EDT - 1 year ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

Oct 24, 2023, 3:19 PM EDT - 1 year ago

A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free

PFE

Oct 24, 2023, 9:25 AM EDT - 1 year ago

Roivant Sciences: Risk-Transforming Deal Met With Crickets

Oct 23, 2023, 3:25 PM EDT - 1 year ago

Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion

PFE

Oct 23, 2023, 8:36 AM EDT - 1 year ago

Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion

PFE

Oct 23, 2023, 6:55 AM EDT - 1 year ago

Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion

PFE

Oct 23, 2023, 1:00 AM EDT - 1 year ago

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

Oct 23, 2023, 12:00 AM EDT - 1 year ago

Roivant Sciences stock: Good news for Vivek Ramaswamy

Sep 26, 2023, 10:12 PM EDT - 1 year ago

Roivant stock price outlook: strong pipeline is a catalyst

Sep 26, 2023, 6:00 AM EDT - 1 year ago

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Sep 11, 2023, 1:08 PM EDT - 1 year ago

Skin In The Game: Behind Roivant's Significant Rise

Sep 9, 2023, 11:17 AM EDT - 1 year ago

Roivant Sciences: Is this Vivek Ramaswamy's biotech stock a buy?

Aug 17, 2023, 4:05 PM EDT - 1 year ago

Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants

Aug 14, 2023, 8:20 PM EDT - 1 year ago

Roivant Sciences Ltd. (ROIV) Q1 2023 Earnings Call Transcript

Aug 14, 2023, 7:00 AM EDT - 1 year ago

Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update

Aug 2, 2023, 4:05 PM EDT - 1 year ago

Roivant Announces Redemption of Outstanding Warrants